A FATAL CASE OF BILATERAL INTERSTITIAL PNEUMONIA (BLIP): INTERFERON ALPHA 2 A INDUCED. by o, Balaji et al.
Vol 10, Issue 10, 2017
Online - 2455-3891 
Print - 0974-2441
A FATAL CASE OF BILATERAL INTERSTITIAL PNEUMONIA (BLIP): INTERFERON ALPHA 2 A 
INDUCED
BALAJI O1, BAIRY KL1*, AMITA PRIYA D1, JOSEPH THOMAS2, NAVIN PATIL1
1Department of Pharmacology, Kasturba Medical College, Manipal University, Manipal, Karnataka, India. 2Department of Medical 
Oncology, Kasturba Medical College, Manipal University, Manipal, Karnataka, India. Email: navin903@gmail.com
Received: 13 April 2017, Revised and Accepted: 07 July 2017
ABSTRACT
Adult T-cell leukemia/lymphoma (ATLL) is a rare lymph proliferative disorder of mature CD4 T-cells caused by the human T-lymph tropic type 1 
(HTLV 1) of retrovirus family. Combination of zidovudine and interferon Alfa combination is one of most commonly used regimen. Many drugs are 
implicated in causing interstitial lung disease. Hence, we report a case of interferon Alfa-induced bilateral interstitial pneumonia in a 32-year-old 
female patient diagnosed with ATLL with HTLV 1 positivity.
Keywords: Pneumonia, Interferon, Zidovudine, Adult T-cell leukemia.
INTRODUCTION
Adult T-cell leukemia/lymphoma (ATLL) is a rare lymph proliferative 
disorder of mature CD4 T-cells caused by the human T-lymph trophic 
type 1 (HTLV) of retrovirus family first recognized in 1977 in Kyoto, 
Japan by Uchiyama et al. [1]. Various chemotherapy regimens are used 
in the treatment of this condition. Combination of zidovudine and 
interferon Alfa combination is one of most commonly used because of 
higher response rates and durability [2]. Many drugs are implicated in 
causing interstitial lung disease and bronchiolitis obliterans organizing 
pneumonia (BOOP) [3]. Global incidence of drug-induced interstitial 
lung disease ranges from 2.5% to 3% [4]. Hence, we report a case of 
interferon Alfa-induced bilateral interstitial pneumonia in a 32-year-
old female patient diagnosed with ATLL with HTLV 1 positivity.
CASE REPORT
Informed consent was taken from the patient. A 32-year-old female 
patient presented with fatigue, weakness, and left shoulder pain. 
There was no pallor, edema, icterus, cyanosis, clubbing, and associated 
weight loss with a negative history of blood loss, no loss of appetite. 
On examination splenomegaly, cervical/axillary lymphadenopathy 
was noted. Family history was insignificant. The patient was not a 
smoker/alcoholic. The patient was readmitted 10 days later with 
c/o of popular eruptions all over the body. Chest X-ray was normal 
(Fig. 1). Liver and renal function tests were normal. Coagulation 
profile was normal. Blood counts were normal except for elevation of 
total leukocyte count. Peripheral smear showed features suggestive of 
hematological malignancy. 84% abnormal lymphocytes were noted on 
bone marrow aspirate suggestive of ATLL. It was confirmed with flow 
cytometry which showed CD3, CD4, CD5, and CD25 positivity. Biopsy 
of lymph nodes finally confirmed ATLL. Skin biopsy showed lymphoid 
cells. Antibodies to HIV 1, HIV 2, HCV, HBV was non-reactive. HTLV 1 
serology was positive. The patient was started on zidovudine 1 g daily 
and interferon alpha 2A, 9 million units s.c once daily. After 7 days’ 
patient complaint of dyspnea, dry cough, 02 saturation 84%. X-ray 
revealed acute respiratory distress syndrome (ARDS) (Fig. 2). There 
was no fever and sputum production. After 10 days, bilateral interstitial 
pneumonia (IP) developed and CT scan confirmed it (Fig. 3). Interferon 
was suspected to be the causal agent and was discontinued. Mechanical 
ventilation of non invasive form was given and patient was maintained 
on bi- level positive  BIPAP positive airway pressure. Patient condition 
did not improve and there was a difficulty in weaning of ventilator. 
Oxygen saturation did not improve and there was cardiac arrest twice 
and successful resuscitation was done to save the life of patient. Patient 
expired on third arrest.
DISCUSSION
ATLL is a rare lymph proliferative disorder of mature CD4 T-cells 
caused by the HTLV of retrovirus family first recognized in 1977 in 
Kyoto, Japan by Uchiyama et al. [1]. It is transmitted from individual to 
individual mainly through sexual contact, blood transfusions, sharing of 
intravenous needles, and through breast milk from carrier mother-to-
new born through breast milk. India being a non-endemic region only 
few case reports are reported with recent upsurge in southern parts 
of India [5]. The prevalence of HTLV 1 in HIV negative individuals is 
only 0.3% in India and so far, only nine cases have been reported from 
India [5]. Zidovudine with interferon Alfa is one of the most widely 
used combination in the treatment of ATLL caused by HTLV 1 infections 
and studies have noted increased durability and higher response rates 
with this combination [6]. Zidovudine main mechanism is terminating 
DNA replication by its cytostatic effects and blocks the transformation 
of normal peripheral-blood lymphocytes [6]. Interferon Alfa acts by 
inhibition of protein synthesis and hence cell growth. It also inhibits the 
expression of major histocompatibility complex 1 and 2 [7]. When used 
in combination it is also thought to enhance the action of zidovudine. 
Major toxicities include hepatic and hematological toxicity.
Many drugs are implicated in causing interstitial lung disease and 
global incidence of drug-induced interstitial lung disease ranges from 
2.5% to 3% [4]. Many studies states that it is usually underreported and 
hence frequency is unknown. Many anti-inflammatory, antimicrobials, 
anticancer drugs, biologicals, and cardiovascular drugs have been 
implemented to cause interstitial lung disease, and interferon is also one 
among them [8]. Incidence of interferon causing IP ranges from 0.01% 
to 0.3% globally [9] and the spectrum of pulmonary toxicities ranges 
from pulmonary sarcoidosis, IP, BOOP, pleural effusion, and exacerbation 
of bronchial asthma to ARDS [10]. Postulated mechanism by which 
interferon causes lung tissue fibrosis is by inhibiting suppressor T-cells, 
increasing cytotoxic T-cells [11]. It is also said to induce proinflammatory 
cytokines and cause excess release of fibrinogenic cytokines [11].
In our case, patient was started on zidovudine and interferon 
combination and on 7th day he complained of dyspnea and ARDS was 
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suspected and X-ray chest confirmed presence of ground glass opacities 
and contrast-enhanced computed tomography was taken, as it is the 
gold standard in diagnosing IP and it confirmed the presence of bilateral 
IP with ground glass opacification. Immediately drug was stopped, and 
antibiotic was given and patient was put on non-invasive ventilation. 
He was put on BiPAP for maintenance, but patient condition did not 
improve and SpO2 kept deteriorating. Patient had 2 cardiac arrests and 
was resuscitated successfully but expired following third arrest.
Hence, causality assessment using Naranjo scale [12] was done and a 
probable causal relationship was established. Adverse drug event was 
found be highly severe and not preventable as per Hartwig’s severity 
and Thornton’s preventability scaling, respectively [13,14].
CONCLUSION
Incidence of drug-induced IP is very low and since interferon is main 
stay in the treatment of ATLL along with zidovudine proper care must 
be taken to avoid lung complications as we report here a death due 
to interferon Alfa. Serial chest X-ray monitoring is required during 
treatment and drug should be withdrawn immediately if sign of 
pulmonary disease develop. Hence, adverse drug monitoring studies 
are necessary, and clinical prospective studies can be undertaken.
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Fig. 1: Before interferon therapy - normal X-ray
Fig. 2: Development of acute respiratory distress syndrome with 
signs of interstital pneumonia after interferon therapy
Fig. 3: Computed tomography chest showing bilateral interstitial 
pneumoni
